1 gen 1998 anni - Trastuzumab
Descrizione:
For the treatment of women with HER2-positive metastatic breast cancer, the Food and Drug Administration (FDA) recommends trastuzumab, a monoclonal antibody that inhibits cancer cells that overproduce the HER2 protein.
Aggiunto al nastro di tempo:
Data: